Fundraising FoxCellerant Therapeutics
San Carlos, US · Delaware corporation
Find your way into Cellerant Therapeutics
Sign up to see every warm intro you have to Cellerant Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cellerant Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
RM
Ramkumar MandalamExecutive
SG
Stephen GreenbergNamed on SEC filing
GS
Gisela SchwabNamed on SEC filing
RY
Rodney YoungNamed on SEC filing
RG
Richard G. RathmannNamed on SEC filing
RH
Robby HogleNamed on SEC filing
Board
RC
Richard ChyetteBoard director
LS
Lowell SearsBoard director
Reported raises · per SEC filings
Form D private placements$8.7M disclosed across 2 rounds · 2014–2016
▶$6.5MraisedFeb 2019 · 10 investors · BiotechnologyRule 506(c)
▶$6.5MraisedFeb 2019 · 10 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Stephen GreenbergDirector
- Gisela SchwabDirector
- Rodney YoungExecutive Officer
- Richard G. RathmannDirector
- Ramkumar MandalamExecutive Officer, Director
- Robby HogleDirector
- Offering amount
- $10M
- Amount sold
- $6.5M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2.2MraisedJan 2014 · 5 investors · BiotechnologyRule 506(c)
▶$2.2MraisedJan 2014 · 5 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Richard ChyetteDirector
- Ramkumar MandalamExecutive Officer, Director
- Lowell SearsDirector
- Stephen GreenbergDirector
- Richard G. RathmannDirector
- Gisela SchwabDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $223.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2013 | $200.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $194.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2007 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $296.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $804.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- How much funding has Cellerant Therapeutics raised?
- Cellerant Therapeutics has disclosed $8.7M raised across 2 rounds.
- Where is Cellerant Therapeutics headquartered?
- Cellerant Therapeutics is headquartered in San Carlos, US.